Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
allergies
Biotech
BMS backs out of Dupixent fight, axing asset despite phase 3 win
BMS dropped plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumped the brakes on a would-be Sotyktu successor.
Nick Paul Taylor
Feb 7, 2025 6:26am
Rapt pays $35M for challenger to Novartis, Roche drug
Dec 23, 2024 8:10am
Holoclara wriggles into ph. 1, sets sights on immune disease
Dec 18, 2024 9:05am
Food allergy biotech DBV is running out of cash
Mar 8, 2024 10:30am
Could Dupixent find a new life targeting 'memory' B cells?
Feb 9, 2024 11:50am
Altamira lays off 25% of staff weeks after allergy spray spinoff
Dec 11, 2023 9:58am